Signal

Alphabet's Isomorphic Labs raised a $5B Series C led by Sequoia and Greenoaks, after raising $2.1B in May and $600M in March 2025, to accelerate clinical trials

First reported by Bloomberg ·

The signal ●●●● Compiled by AI from Bloomberg, Techmeme, Isomorphic Labs and Startup.eu
Why you might care

The pace of AI drug discovery funding has accelerated significantly, with over $8 billion raised by Isomorphic Labs alone in under a year.

What happened

Isomorphic Labs, Alphabet's AI drug discovery unit, has secured $5 billion in a Series C funding round. The investment was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz (a16z) and continued significant investment from Alphabet. All existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund, also participated. This substantial capital injection follows two previous rounds in 2025, totaling $2.7 billion ($2.1 billion in May and $600 million in March). Isomorphic Labs intends to use the funds to accelerate its clinical trials and scale its proprietary AI-powered drug design engine, IsoDDE, to develop new medicines.

What it means

This massive funding round underscores the significant investor confidence in AI's transformative potential within the pharmaceutical industry. Isomorphic Labs' ability to raise such substantial capital in a short period indicates a strong belief in its AI-driven drug design engine and its potential to accelerate the traditionally lengthy and expensive drug development process. The continued involvement of Alphabet and the influx of major venture capital firms suggest a competitive landscape where AI-native biotechs are positioning themselves as key players in future therapeutic innovation.

The success of Isomorphic Labs signals a potential shift in how new medicines are discovered and brought to market, potentially leading to faster development cycles and novel treatments for unmet medical needs. For patients, this could mean quicker access to innovative therapies. For the broader biotech and AI sectors, it highlights the immense investment flowing into AI-as-a-service for drug discovery, creating a benchmark for other companies in the space and potentially influencing future research and development strategies across the industry.

AI-written summary. May contain errors.

Google Funding